Hepatology International

Papers
(The H4-Index of Hepatology International is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
The safety profile of endoscopic variceal ligation in patients with esophageal varices110
HBV in pregnancy: time to consider tenofovir alafenamide (TAF)95
Metabolically healthy obese and MAFLD: does weight status alone matter?80
Platelets in acute liver failure: an innocent bystander or instigator?78
Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial63
Diagnosis of significant liver fibrosis in patients with chronic hepatitis B using a deep learning-based data integration network61
Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk60
N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD57
‘First week’ is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure55
Good outcomes of living donor liver transplant in primary sclerosing cholangitis: an experience from North India43
Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression43
The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease43
Antibiotic prophylaxis in upper gastrointestinal bleeding with Child-Pugh A cirrhosis: need for objective infection markers and broader studies43
The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes42
Effect of microbiota metabolites on the progression of chronic hepatitis B virus infection41
Methodological reflections on vasoconstrictor use in refractory ascites: bridging trial rigor and real-world relevance40
Pure laparoscopic versus open left lateral hepatectomy in pediatric living donor liver transplantation: a review and meta-analysis37
Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study37
Response to: “Is laparoscopic hepatectomy superior to laparotomic hepatectomy? The debate continues”36
Antioxidant, selenium and risk of nonalcoholic fatty liver disease, more than causality35
Impact of CT-relevant skeletal muscle parameters on post-liver transplantation survival in patients with hepatocellular carcinoma34
Predictive value of soluble PD-1 for HBsAg loss in HbeAg-negative patients with chronic hepatitis B: results from a prospective study34
Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets33
Commentary on “Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled t32
Development of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection32
Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis32
Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies31
Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy31
Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria30
Exosome GLUT1 derived from hepatocyte identifies the risk of non-alcoholic steatohepatitis and fibrosis29
Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis29
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis29
0.14145421981812